Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

This phase I trial will escalate doses of the histone deacetylase inhibitor (HDAC) vorinostat
to a chemoradiation platform for cisplatin, pemetrexed and radiation to a dose of 70Gy in
NSCLC patients with unresectable IIIA and dry IIIB disease. The endpoint will be to determine
MTD of the combination.

Inclusion Criteria:

- biopsy proven non-squamous NSCLC with unresectable stage IIIA or dry IIIB disease.

- FEV1 >/= 1 liter

- ECOG PS 0 or 1

- Able to swallow and absorb enterally

- Measurable disease per RECIST 1.1

- Adequate organ and marrow function including calculated creatinine clearance >/= 60
mL/min hepatic enzymes and alk phos
Exclusion Criteria:

- Chemotherapy or radiotherapy nitrosureas)

- Active bleeding

- Known brain mets

- Prior thoracic radiotherapy that would lead to overlap with current radiation field.

- More than 10% weight loss in 6 months.

- Pancoast tumors, supraclavicular or contralateral hilar lymph node involvement

- Known HIV positive

- Prior treatment with an HDAC inhibitor